Morning Note – 30 September 2022

4basebio - Interims demonstrate sustained technological progress

4basebio’s half-year results for period ended 30 June 2021 reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase

Morning Note – 10 June 2022

Morning Note – 9 May 2022

4basebio - FY 2021 results

4basebio’s full-year results to 31 December 2021 reflect consistent progress towards its main objectives, with recently completed clean rooms undergoing validation ahead of targeted DNA production towards the year end. It generated revenues of £0.34m with a pre-tax loss of £3.64m (FY 2020: £0.72m) and ended the period with £9.6m cash, providing it with a cash runway into 2023 and an undrawn loan facility of €25m. When fully operational, this facility will be able to produce DNA with a value in e

Rude Health - finnCap Life Sciences quarterly sector note

The smaller cap Healthcare index: After another year of outperformance, during which the AIM healthcare sector rose 10% in 2021 vs 5% for the broader AIM market, we are seeing a rotation out of growth into value stocks in 2022 (this also helped the large cap healthcare stocks rise 17% in 2021). Coupled with a rotation out of COVID-19 diagnostics companies, the AIM Healthcare index has fallen 24% in 2022 YTD (vs AIM -14%). The finnLife 50 index has also fallen, by 27%, with all but two companies

Morning Note – 15 February 2022

Morning Note – 18 January 2022

Morning Note – 23 November 2021

Morning Note – 30 September 2021

4basebio - Promising interims but recent manufacturing news is key event

4basebio’s half-year results for period ended 30 June 2021 reflect consistent progress towards its main objectives. It generated revenues of £0.18m with a pre-tax loss of £1.85m (H1 2020: £0.38m, +385%) and ended the period with £12.1m cash, providing it with a cash runway beyond 2023. The recent start of the development of a Good Manufacturing Practice (GMP) facility is a pivotal event, demonstrating that its validated lab processes can be transferred to pilot-scale manufacture. When fully oper

Small Cap Feast: 22/06/21

Joiners: Thor Explorations (TSXV:THX;THX.L) has completed a secondary listing on AIM. . Segun Lawson, President & CEO, stated: "Today's admission to the AIM market of the London Stock Exchange represents another milestone in the development of the Company, offering wider access for investors as we progress through a transformational period in the Company's development. We continue to focus on pouring first gold at the Segilola Project in Nigeria in July 2021, targeting publication of a Maiden r

4basebio - FY2020: setting the stage for next-generation technology

Full year results for the year ended 31 December 2020 reflect a period of change for the company as it sets the stage for the commercialisation of its next-generation DNA synthesis and delivery technology. 4basebio UK Societas was spun out of 4basebio AG (now 2Invest AG) on 8 December 2020, and was admitted to AIM on 17 February 2021. 4basebio generated revenues of £0.46m (2019: £0.20m, +129%), with a pre-tax loss of £0.72m (2019: £0.53m, +35%), with year-end cash of £15.0m (versus our £14.6m es

Small Cap Feast

Alphawave IP Group is considering an IPO on the standard listing segment of the London Stock Exchange. Alphawave IP is a leading semiconductor IP company focusing on the hardest-to-solve connectivity challenges created by the exponential growth of data. Funds and accounts managed by BlackRock, and Janus Henderson, have each entered into cornerstone agreements with the Company to subscribe for, subject to certain conditions, in aggregate, c. USD 510m of Offer Shares at an offer price representing

Morning Note – 27 April 2021

Initial Equity Trading Comments - 15 May 2023

LIBERUM: Aptamer* - Prelims supports growth projections

Kromek - Placing raises £7m with Open Offer of up to £1m

Kromek raised £7m (with up to £1m via an Open Offer) to strengthen the balance sheet and provide the working capital for the CT programme to bridge the gap before supply agreements with recently announced Tier 1 and Tier 2 OEMs commence in earnest. As the only independent commercial scale manufacturer of the next-generation detector (CZT) for use in CT and SPECT imaging systems, Kromek is actively engaged with 9 OEMs (both Tier 1 and Tier 2), with 3 agreements having now been signed (FC estimate

LIBERUM: Aptamer* - Initiation - Build better binders

Morning Note – 5 June 2023

Tristel - FDA approval: entering the world’s largest ultrasound market

Tristel received FDA clearance to market Tristel ULT as a high-level disinfectant (HLD) for use on endocavity ultrasound probes and skin surface transducers that may contact non-intact skin. This is a significant and arguably long-awaited, value-enhancing milestone for the company, enabling it to market DUO in the single largest ultrasound market in the world: a market with c.215m annual procedures and one that Tristel is very familiar with, given ultrasound accounts for c.50% of its annual reve

Hybridan Small Cap Feast - 19 May 23

19th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Oxford BioDynamics+ (OBD, House Stock, 17p) - Expanding applications

NetScientific - FY 2022 results, portfolio value increases 35%

NetScientific, an investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies announces its FY 2022 results demonstrating a 35% increase in portfolio value to £41.8m across an expanding portfolio of 24 companies. NSCI reports that its portfolio has raised c. £70m. In line with its capital light investment strategy, NSCI/EMV have supported these fund-raises selectively through £3.2m of direct investments and loans, an

2022 a year of progress

FY22 results were in line with expectations, with cash at period end of $9.8m, giving a cash runway into mid-24. Verici continues to demonstrate strong operational and strategic progress and transitioned from a research only company to a commercial revenue-generating company in January with the launch of its first product Tutivia. Notable progress has been made in securing reimbursement, including the proposed price of $2,650/test being significantly ahead of the assumed rate of $1,500 in our mo

Destiny Pharma plc (DEST) - House Stock at 35p - Stars aligning

Initial Equity Trading Comments - 10 May 2023

Avon Protection - Termination of coverage

Edison Investment Research is terminating coverage on Avon Protection (AVON), Osirium Technologies (OSI), IQE (IQE), Kopy Goldfields (KOBY) and RhoVac (ROHVAC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Diaceutics - $10m Contract Win

Diaceutics has announced a new US$10.1m multi-year enterprise engagement with a top 10 global pharma company covering a wide range of Diaceutics' subscription data services to be delivered via the company's DXRX platform. The three-year contract includes additional options which could result in a significant increase in the scope and value of the contract.

April Operational Update

Belluscura has released an operational update which reports it has started manufacturing in China, that the DISCOV-R won the Silver Award in the Best New Product category at MedTrade and trading is in line with expectations.